UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas
Neuroendocrine carcinomas, such as neuroendocrine prostate cancer and small-cell lung cancer, commonly have a poor prognosis and limited therapeutic options. We report that ubiquitin carboxy-terminal hydrolase L1 (UCHL1), a deubiquitinating enzyme, is elevated in tissues and plasma from patients wit...
Saved in:
Published in | Cell reports. Medicine Vol. 5; no. 2; p. 101381 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
20.02.2024
Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Neuroendocrine carcinomas, such as neuroendocrine prostate cancer and small-cell lung cancer, commonly have a poor prognosis and limited therapeutic options. We report that ubiquitin carboxy-terminal hydrolase L1 (UCHL1), a deubiquitinating enzyme, is elevated in tissues and plasma from patients with neuroendocrine carcinomas. Loss of UCHL1 decreases tumor growth and inhibits metastasis of these malignancies. UCHL1 maintains neuroendocrine differentiation and promotes cancer progression by regulating nucleoporin, POM121, and p53. UCHL1 binds, deubiquitinates, and stabilizes POM121 to regulate POM121-associated nuclear transport of E2F1 and c-MYC. Treatment with the UCHL1 inhibitor LDN-57444 slows tumor growth and metastasis across neuroendocrine carcinomas. The combination of UCHL1 inhibitors with cisplatin, the standard of care used for neuroendocrine carcinomas, significantly delays tumor growth in pre-clinical settings. Our study reveals mechanisms of UCHL1 function in regulating the progression of neuroendocrine carcinomas and identifies UCHL1 as a therapeutic target and potential molecular indicator for diagnosing and monitoring treatment responses in these malignancies.
[Display omitted]
•UCHL1 is a potential molecular indicator for neuroendocrine carcinomas•UCHL1 regulates neuroendocrine carcinoma tumor growth and metastasis•UCHL1 stabilizes POM121 and regulates POM121-driven E2F1 nuclear localization•UCHL1 is a therapeutic target for neuroendocrine carcinomas and neuroblastoma
Liu et al. identify UCHL1 as a blood and tissue marker that is elevated across cancers with neuroendocrine features. These cancers are characterized by poor patient outcomes and lack effective treatments. UCHL1 inhibition exhibits anticancer effects in malignancies with neuroendocrine features, presenting a potent therapeutic strategy for these patients. |
---|---|
AbstractList | Neuroendocrine carcinomas, such as neuroendocrine prostate cancer and small-cell lung cancer, commonly have a poor prognosis and limited therapeutic options. We report that ubiquitin carboxy-terminal hydrolase L1 (UCHL1), a deubiquitinating enzyme, is elevated in tissues and plasma from patients with neuroendocrine carcinomas. Loss of UCHL1 decreases tumor growth and inhibits metastasis of these malignancies. UCHL1 maintains neuroendocrine differentiation and promotes cancer progression by regulating nucleoporin, POM121, and p53. UCHL1 binds, deubiquitinates, and stabilizes POM121 to regulate POM121-associated nuclear transport of E2F1 and c-MYC. Treatment with the UCHL1 inhibitor LDN-57444 slows tumor growth and metastasis across neuroendocrine carcinomas. The combination of UCHL1 inhibitors with cisplatin, the standard of care used for neuroendocrine carcinomas, significantly delays tumor growth in pre-clinical settings. Our study reveals mechanisms of UCHL1 function in regulating the progression of neuroendocrine carcinomas and identifies UCHL1 as a therapeutic target and potential molecular indicator for diagnosing and monitoring treatment responses in these malignancies. Neuroendocrine carcinomas, such as neuroendocrine prostate cancer and small-cell lung cancer, commonly have a poor prognosis and limited therapeutic options. We report that ubiquitin carboxy-terminal hydrolase L1 (UCHL1), a deubiquitinating enzyme, is elevated in tissues and plasma from patients with neuroendocrine carcinomas. Loss of UCHL1 decreases tumor growth and inhibits metastasis of these malignancies. UCHL1 maintains neuroendocrine differentiation and promotes cancer progression by regulating nucleoporin, POM121, and p53. UCHL1 binds, deubiquitinates, and stabilizes POM121 to regulate POM121-associated nuclear transport of E2F1 and c-MYC. Treatment with the UCHL1 inhibitor LDN-57444 slows tumor growth and metastasis across neuroendocrine carcinomas. The combination of UCHL1 inhibitors with cisplatin, the standard of care used for neuroendocrine carcinomas, significantly delays tumor growth in pre-clinical settings. Our study reveals mechanisms of UCHL1 function in regulating the progression of neuroendocrine carcinomas and identifies UCHL1 as a therapeutic target and potential molecular indicator for diagnosing and monitoring treatment responses in these malignancies. • UCHL1 is a potential molecular indicator for neuroendocrine carcinomas • UCHL1 regulates neuroendocrine carcinoma tumor growth and metastasis • UCHL1 stabilizes POM121 and regulates POM121-driven E2F1 nuclear localization • UCHL1 is a therapeutic target for neuroendocrine carcinomas and neuroblastoma Liu et al. identify UCHL1 as a blood and tissue marker that is elevated across cancers with neuroendocrine features. These cancers are characterized by poor patient outcomes and lack effective treatments. UCHL1 inhibition exhibits anticancer effects in malignancies with neuroendocrine features, presenting a potent therapeutic strategy for these patients. Neuroendocrine carcinomas, such as neuroendocrine prostate cancer and small-cell lung cancer, commonly have a poor prognosis and limited therapeutic options. We report that ubiquitin carboxy-terminal hydrolase L1 (UCHL1), a deubiquitinating enzyme, is elevated in tissues and plasma from patients with neuroendocrine carcinomas. Loss of UCHL1 decreases tumor growth and inhibits metastasis of these malignancies. UCHL1 maintains neuroendocrine differentiation and promotes cancer progression by regulating nucleoporin, POM121, and p53. UCHL1 binds, deubiquitinates, and stabilizes POM121 to regulate POM121-associated nuclear transport of E2F1 and c-MYC. Treatment with the UCHL1 inhibitor LDN-57444 slows tumor growth and metastasis across neuroendocrine carcinomas. The combination of UCHL1 inhibitors with cisplatin, the standard of care used for neuroendocrine carcinomas, significantly delays tumor growth in pre-clinical settings. Our study reveals mechanisms of UCHL1 function in regulating the progression of neuroendocrine carcinomas and identifies UCHL1 as a therapeutic target and potential molecular indicator for diagnosing and monitoring treatment responses in these malignancies. [Display omitted] •UCHL1 is a potential molecular indicator for neuroendocrine carcinomas•UCHL1 regulates neuroendocrine carcinoma tumor growth and metastasis•UCHL1 stabilizes POM121 and regulates POM121-driven E2F1 nuclear localization•UCHL1 is a therapeutic target for neuroendocrine carcinomas and neuroblastoma Liu et al. identify UCHL1 as a blood and tissue marker that is elevated across cancers with neuroendocrine features. These cancers are characterized by poor patient outcomes and lack effective treatments. UCHL1 inhibition exhibits anticancer effects in malignancies with neuroendocrine features, presenting a potent therapeutic strategy for these patients. |
ArticleNumber | 101381 |
Author | Liss, Michael A. Huang, Jiaoti Garcia-Marques, Fernando Shaw Toland, Angus Martin Massey, Christopher F. Stoyanova, Tanya Weissman, Irving L. Baron, Maya Chin, Arnold I. Pitteri, Sharon J. Aslan, Merve Bermudez, Abel Corey, Eva Nolley, Rosalie Hartono, Alifiani B. Brooks, James D. Howitt, Brooke E. Nguyen, Holly M. Soh, H. Tom Kunder, Christian A. Zoubeidi, Amina Das, Millie Yin, Qingqing Hsu, En-Chi Lee, Chung S. Liu, Shiqin Shen, Michelle Zheng, Liwei Chai, Timothy Denning, Caden J. |
Author_xml | – sequence: 1 givenname: Shiqin surname: Liu fullname: Liu, Shiqin organization: Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA – sequence: 2 givenname: Timothy surname: Chai fullname: Chai, Timothy organization: Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, USA – sequence: 3 givenname: Fernando surname: Garcia-Marques fullname: Garcia-Marques, Fernando organization: Department of Radiology, Stanford University, Palo Alto, CA, USA – sequence: 4 givenname: Qingqing surname: Yin fullname: Yin, Qingqing organization: Department of Radiology, Stanford University, Palo Alto, CA, USA – sequence: 5 givenname: En-Chi surname: Hsu fullname: Hsu, En-Chi organization: Department of Radiology, Stanford University, Palo Alto, CA, USA – sequence: 6 givenname: Michelle surname: Shen fullname: Shen, Michelle organization: Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA – sequence: 7 givenname: Angus Martin surname: Shaw Toland fullname: Shaw Toland, Angus Martin organization: Department of Pathology, Stanford University, Stanford, CA, USA – sequence: 8 givenname: Abel surname: Bermudez fullname: Bermudez, Abel organization: Department of Radiology, Stanford University, Palo Alto, CA, USA – sequence: 9 givenname: Alifiani B. surname: Hartono fullname: Hartono, Alifiani B. organization: Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA – sequence: 10 givenname: Christopher F. surname: Massey fullname: Massey, Christopher F. organization: Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA – sequence: 11 givenname: Chung S. surname: Lee fullname: Lee, Chung S. organization: Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA – sequence: 12 givenname: Liwei surname: Zheng fullname: Zheng, Liwei organization: Department of Radiology, Stanford University, Palo Alto, CA, USA – sequence: 13 givenname: Maya surname: Baron fullname: Baron, Maya organization: Department of Pediatrics, Stanford University, Stanford, CA, USA – sequence: 14 givenname: Caden J. surname: Denning fullname: Denning, Caden J. organization: Department of Radiology, Stanford University, Palo Alto, CA, USA – sequence: 15 givenname: Merve surname: Aslan fullname: Aslan, Merve organization: Department of Radiology, Stanford University, Palo Alto, CA, USA – sequence: 16 givenname: Holly M. surname: Nguyen fullname: Nguyen, Holly M. organization: Department of Urology, University of Washington, Seattle, WA, USA – sequence: 17 givenname: Rosalie surname: Nolley fullname: Nolley, Rosalie organization: Department of Urology, Stanford University, Stanford, CA, USA – sequence: 18 givenname: Amina surname: Zoubeidi fullname: Zoubeidi, Amina organization: Department of Urologic Sciences, University of British Columbia, Vancouver, BC V6H 3Z6, Canada – sequence: 19 givenname: Millie surname: Das fullname: Das, Millie organization: Department of Medicine, VA Palo Alto Health Care System, Palo Alto, CA, USA – sequence: 20 givenname: Christian A. surname: Kunder fullname: Kunder, Christian A. organization: Department of Pathology, Stanford University, Stanford, CA, USA – sequence: 21 givenname: Brooke E. surname: Howitt fullname: Howitt, Brooke E. organization: Department of Pathology, Stanford University, Stanford, CA, USA – sequence: 22 givenname: H. Tom surname: Soh fullname: Soh, H. Tom organization: Department of Radiology, Stanford University, Palo Alto, CA, USA – sequence: 23 givenname: Irving L. surname: Weissman fullname: Weissman, Irving L. organization: Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, USA – sequence: 24 givenname: Michael A. surname: Liss fullname: Liss, Michael A. organization: Department of Urology, UT Health San Antonio, San Antonio, TX, USA – sequence: 25 givenname: Arnold I. surname: Chin fullname: Chin, Arnold I. organization: Department of Urology, University of California, Los Angeles, Los Angeles, CA, USA – sequence: 26 givenname: James D. surname: Brooks fullname: Brooks, James D. organization: Department of Urology, Stanford University, Stanford, CA, USA – sequence: 27 givenname: Eva surname: Corey fullname: Corey, Eva organization: Department of Urology, University of Washington, Seattle, WA, USA – sequence: 28 givenname: Sharon J. surname: Pitteri fullname: Pitteri, Sharon J. organization: Department of Radiology, Stanford University, Palo Alto, CA, USA – sequence: 29 givenname: Jiaoti surname: Huang fullname: Huang, Jiaoti organization: Department of Pathology, Duke University, Durham, NC, USA – sequence: 30 givenname: Tanya surname: Stoyanova fullname: Stoyanova, Tanya email: tstoyanova@mednet.ucla.edu organization: Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38244540$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kU1r3DAQhkVJaT6aP9BD0bGX3erTlqFQytIkhYVemmMRY3mcaLGlrSQvyb-vzSYhvfQkoXnnfWf0nJOTEAMS8oGzNWe8-rxbP7g0rgUTcnmQhr8hZ6KqqpWsG37y6n5KLnPeMcaE5txI9o6cSiOU0oqdkd-3m5stpz5ToPtYMBQPAx3jgG4aIFEfOu-gxEQhdLTcY4I9TsU7WiDdYaH9XAo4pYihiy75gNRBcj7EEfJ78raHIePl03lBbq--_9rcrLY_r39svm1XTumqrIwSqtVcQqewr1oNBmSvOzSKCcEYyoaDNqZqG857IREBTAuoZF23oje1vCBfj777qR2xc_MaCQa7T36E9GgjePtvJfh7excPljPT1Frw2eHTk0OKfybMxY4-OxwGCBinbEXDa1NJo5cwcZS6FHNO2L_kcGYXNnZnFzZ2YWOPbOamj68nfGl5JjELvhwFOP_TwWOy2XkMDjuf0BXbRf8__79KpqNs |
CitedBy_id | crossref_primary_10_1371_journal_pone_0303440 |
Cites_doi | 10.1038/s41467-022-31331-2 10.1016/j.jid.2017.03.024 10.1158/1078-0432.CCR-13-1982 10.1200/JCO.21.01881 10.1056/NEJMra0804577 10.1038/srep28203 10.1158/1078-0432.CCR-09-3178 10.1001/jamaoncol.2022.5631 10.1111/cas.14284 10.1126/science.aat5749 10.1634/theoncologist.2017-0624 10.1073/pnas.1902651116 10.1038/s41467-018-08133-6 10.1158/1078-0432.CCR-21-2225 10.1007/s12022-022-09708-2 10.1038/nature14664 10.1158/2159-8290.CD-11-0130 10.1126/sciadv.aax4826 10.3233/CBM-210001 10.1038/s41586-019-1186-3 10.7150/jca.33368 10.1016/S0092-8674(02)01012-7 10.1093/bioinformatics/btr645 10.1006/jsbi.2000.4212 10.1016/j.semcancer.2022.05.007 10.1016/j.cell.2016.01.034 10.1158/2159-8290.CD-15-1263 10.1158/0008-5472.CAN-20-3351 10.1172/JCI90793 10.1038/nm.4045 10.1016/j.pharmthera.2022.108255 10.1038/s41375-020-0958-y 10.1073/pnas.191502998 10.1016/S0140-6736(11)60165-7 10.1038/s41586-021-03985-3 10.1016/j.ccell.2019.06.005 10.1126/science.1106148 10.1158/2159-8290.CD-13-0183 10.1126/science.aah4307 10.1016/j.cell.2018.07.015 10.1021/pr4006958 10.1158/1078-0432.CCR-19-0317 10.1073/pnas.1905384117 10.1021/jacs.0c04527 10.1158/1078-0432.CCR-19-1373 10.1038/s41467-021-27451-w 10.1158/2159-8290.CD-20-0581 10.1186/1479-5876-6-69 10.1038/s41467-019-09784-9 10.1073/pnas.1518007112 10.1089/gtmb.2020.0053 10.1155/2012/123706 10.1073/pnas.241500798 10.1038/s41467-021-23780-y 10.1016/j.chembiol.2003.08.010 10.1038/s41467-018-06177-2 10.1158/1078-0432.CCR-20-4968 10.1038/s41571-022-00643-z 10.1038/nrm.2016.147 10.1080/14737159.2020.1707670 10.1158/1078-0432.CCR-19-0775 10.1016/j.jim.2018.03.004 10.1093/biomethods/bpab014 10.1126/science.aah4199 10.15252/emmm.202012878 10.1038/bjc.2015.188 10.1186/s12943-019-0941-2 10.1182/blood-2018-05-848515 10.1200/JCO.2014.59.4648 10.3390/cells9030559 10.1016/j.ccell.2016.10.019 10.1038/ng.2396 10.3892/ijmm.2012.1012 10.1007/978-1-0716-2201-8_18 10.1200/JCO.2015.65.7270 10.1038/leu.2010.138 10.1038/s41572-020-00235-0 10.1038/s41467-019-13817-8 10.1002/pros.23313 10.1002/0471141755.ph1423s60 10.1038/nrurol.2014.21 |
ContentType | Journal Article |
Copyright | 2023 The Author(s) Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved. 2023 The Author(s) 2023 |
Copyright_xml | – notice: 2023 The Author(s) – notice: Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved. – notice: 2023 The Author(s) 2023 |
DBID | 6I. AAFTH CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 5PM |
DOI | 10.1016/j.xcrm.2023.101381 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
EISSN | 2666-3791 |
EndPage | 101381 |
ExternalDocumentID | 10_1016_j_xcrm_2023_101381 38244540 S2666379123006109 |
Genre | Journal Article |
GrantInformation_xml | – fundername: NCI NIH HHS grantid: P30 CA016086 – fundername: NCI NIH HHS grantid: R37 CA240822 – fundername: NCI NIH HHS grantid: R01 CA244281 – fundername: NCI NIH HHS grantid: R01 CA274978 – fundername: NCI NIH HHS grantid: P50 CA092131 |
GroupedDBID | .1- .FO 53G 6I. AAEDW AAFTH AAXUO ACHIH AFCTW AFRHN AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ EBS FDB GROUPED_DOAJ M41 M~E NCXOZ OK1 ROL RPM Z5R 0R~ AALRI AAMRU ADVLN AITUG CGR CUY CVF ECM EIF NPM 0SF AAYXX CITATION 7X8 5PM |
ID | FETCH-LOGICAL-c456t-8424b513ad4ef6b5a8a3f5de8402200e391a5886b911f23eeaa8bae4377b2f873 |
IEDL.DBID | RPM |
ISSN | 2666-3791 |
IngestDate | Tue Sep 17 21:28:42 EDT 2024 Fri Oct 25 03:00:35 EDT 2024 Thu Sep 26 16:35:16 EDT 2024 Sat Nov 02 12:29:45 EDT 2024 Sat Mar 23 16:41:28 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | neuroblastoma nuclear pore complex UCHL1 small cell lung cancer neuroendocrine carcinomas neuroendocrine prostate cancer |
Language | English |
License | This is an open access article under the CC BY-NC-ND license. Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c456t-8424b513ad4ef6b5a8a3f5de8402200e391a5886b911f23eeaa8bae4377b2f873 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Lead contact |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10897521/ |
PMID | 38244540 |
PQID | 2917863857 |
PQPubID | 23479 |
PageCount | 1 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_10897521 proquest_miscellaneous_2917863857 crossref_primary_10_1016_j_xcrm_2023_101381 pubmed_primary_38244540 elsevier_sciencedirect_doi_10_1016_j_xcrm_2023_101381 |
PublicationCentury | 2000 |
PublicationDate | 2024-02-20 |
PublicationDateYYYYMMDD | 2024-02-20 |
PublicationDate_xml | – month: 02 year: 2024 text: 2024-02-20 day: 20 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Cell reports. Medicine |
PublicationTitleAlternate | Cell Rep Med |
PublicationYear | 2024 |
Publisher | Elsevier Inc Elsevier |
Publisher_xml | – name: Elsevier Inc – name: Elsevier |
References | Hussain, Bedekovics, Liu, Hu, Jeon, Johnson, Vasmatzis, May, Roux, Galardy (bib37) 2018; 132 Li, Tao, Jin, van Hasselt, Poon, Wang, Zeng, Jia, Zeng, Chan, Cao (bib34) 2010; 16 Schuller, Wojtynek, Mankus, Tatli, Kronenberg-Tenga, Regmi, Dip, Lytton-Jean, Brignole, Dasso (bib41) 2021; 598 Liu, Lashuel, Choi, Xing, Case, Ni, Yeh, Cuny, Stein, Lansbury (bib61) 2003; 10 Dechat, Vlcek, Foisner (bib56) 2000; 129 DeRose, Gligorich, Wang, Georgelas, Bowman, Courdy, Welm, Welm (bib82) 2013 Zhang, Zheng, Li, Bei, Zhang, Tian, Song, Zhu, Tan (bib43) 2020; 24 Panyain, Godinat, Lanyon-Hogg, Lachiondo-Ortega, Will, Soudy, Mondal, Mason, Elkhalifa, Smith (bib62) 2020; 142 Shimada, Kudo, Maehara, Matsubayashi, Otaki, Kajiwara, Ohira, Minna, Ikeda (bib71) 2020; 111 Kim, Sun, Storck, Welker Leng, Jenkins, Coleman, Sampson, Guan, Kumaraswamy, Rodansky (bib26) 2021; 27 Rudin, Brambilla, Faivre-Finn, Sage (bib7) 2021; 7 Beck, Hurt (bib40) 2017; 18 Aslan, Hsu, Liu, Stoyanova (bib77) 2021; 6 Ghandi, Huang, Jané-Valbuena, Kryukov, Lo, McDonald, Barretina, Gelfand, Bielski, Li (bib53) 2019; 569 Balanis, Sheu, Esedebe, Patel, Smith, Park, Alhani, Gomperts, Huang, Witte, Graeber (bib49) 2019; 36 Sarbassov, Guertin, Ali, Sabatini (bib83) 2005; 307 Bishop, Thaper, Vahid, Davies, Ketola, Kuruma, Jama, Nip, Angeles, Johnson (bib22) 2017; 7 Mondello, Linnet, Buki, Robicsek, Gabrielli, Tepas, Papa, Brophy, Tortella, Hayes, Wang (bib35) 2012; 70 Liu, Fallon, Lashuel, Liu, Lansbury (bib58) 2002; 111 Guo, Ci, Ahmed, Hua, Soares, Lin, Puca, Vosoughi, Xue, Li (bib9) 2019; 10 Abida, Cyrta, Heller, Prandi, Armenia, Coleman, Cieslik, Benelli, Robinson, Van Allen (bib73) 2019; 116 Nachmias, Schimmer (bib69) 2020; 34 Luo, Wang, Yeh, Sun, Liang, Xiao, Xu, Niu, Cheng, Maity (bib19) 2019; 10 Zhang, Zheng, Zhou, Song, Hulsurkar, Su, Liu, Wang, Shao, Ittmann (bib20) 2018; 9 Yin, Xu, Chang, Zeng, Chen, Wang, Groth, Foo, Liang, Hu, Huang (bib25) 2019; 18 Jiang, Richaud, Vieugué, Rama, Delcros, Siouda, Sanada, Redavid, Ducarouge, Hervieu (bib8) 2021; 13 Petty, Paz-Ares (bib15) 2023; 9 Halabi, Kelly, Ma, Zhou, Solomon, Fizazi, Tangen, Rosenthal, Petrylak, Hussain (bib52) 2016; 34 Chen, Alexe, Dharia, Ross, Iniguez, Conway, Wang, Veschi, Lam, Qi (bib21) 2018; 128 Bi, Zhang, Zhang, Xie, Xia, Du, Li (bib32) 2020; 6 Pinto, Applebaum, Volchenboum, Matthay, London, Ambros, Nakagawara, Berthold, Schleiermacher, Park (bib13) 2015; 33 Navarro, Trevisan-Herraz, Bonzon-Kulichenko, Núñez, Martínez-Acedo, Pérez-Hernández, Jorge, Mesa, Calvo, Carrascal (bib81) 2014; 13 Guan, Zhang, Wang, Jia, Zhang, Yan, Zhao (bib46) 2021; 32 Brady, Bagadion, Singh, Conteduca, Van Emmenis, Arceci, Pakula, Carelli, Khani, Bakht (bib24) 2021; 12 Liu, Alabi, Yin, Stoyanova (bib16) 2022; 86 Amin, Shukla, Zhu, Kim, Wang, Tian, Tran, Paul, Cappell, Burkett (bib65) 2021; 12 Maris (bib2) 2010; 362 Hurst-Kennedy, Chin, Li (bib57) 2012; 2012 Tan, Sood, Rahimi, Wang, Gupta, Hicks, Mosier, Gocke, Epstein, Netto (bib17) 2014; 20 Zhong, Zhao, Ma, Luo, Liu, Wang, Yuan, Sang, Huang (bib39) 2012; 30 Knockenhauer, Schwartz (bib42) 2016; 164 Gatto, Lilley (bib80) 2012; 28 Park, Lee, Sheu, Wang, Balanis, Nguyen, Smith, Cheng, Tsai, Cheng (bib5) 2018; 362 Hsu, Rice, Bermudez, Marques, Aslan, Liu, Ghoochani, Zhang, Chen, Zlitni (bib48) 2020; 117 Qiu, Matthay (bib12) 2022; 19 Alabi, Liu, Stoyanova (bib14) 2022; 238 Nguyen, Vessella, Morrissey, Brown, Coleman, Higano, Mostaghel, Zhang, True, Lam (bib72) 2017; 77 Peifer, Fernández-Cuesta, Sos, George, Seidel, Kasper, Plenker, Leenders, Sun, Zander (bib29) 2012; 44 Almstedt, Elgendy, Hekmati, Rosén, Wärn, Olsen, Dyberg, Doroszko, Larsson, Sundström (bib55) 2020; 11 Unno, Chalmers, Pamarthy, Vatapalli, Rodriguez, Lysy, Mok, Sagar, Han, Yoo (bib10) 2021; 81 George, Lim, Jang, Cun, Ozretić, Kong, Leenders, Lu, Fernández-Cuesta, Bosco (bib70) 2015; 524 Liu, Li, Yang, Geng, Luo, Wu, Manyam, Korentzelos, Park, Tang (bib54) 2019; 25 Nadal, Schweizer, Kryvenko, Epstein, Eisenberger (bib4) 2014; 11 Rodriguez-Bravo, Pippa, Song, Carceles-Cordon, Dominguez-Andres, Fujiwara, Woo, Koh, Ertel, Lokareddy (bib47) 2018; 174 Seo, Jin, Sohn, Park, Lee, Chung (bib59) 2017; 137 Garber, Troyanskaya, Schluens, Petersen, Thaesler, Pacyna-Gengelbach, van de Rijn, Rosen, Perou, Whyte (bib75) 2001; 98 Wang, Sun, Bao, En, Tian, Zhao, Jia (bib44) 2020; 20 Lassman, Wen, van den Bent, Plotkin, Walenkamp, Green, Li, Walker, Chang, Tamir (bib67) 2022; 28 Wang, Teshiba, Ikegaki, Tang, Naranjo, London, Hogarty, Gastier-Foster, Look, Park (bib27) 2015; 113 Hussain, Foreman, Perkins, Witzig, Miles, van Deursen, Galardy (bib38) 2010; 24 Bhattacharjee, Richards, Staunton, Li, Monti, Vasa, Ladd, Beheshti, Bueno, Gillette (bib51) 2001; 98 Rindi, Mete, Uccella, Basturk, La Rosa, Brosens, Ezzat, de Herder, Klimstra, Papotti, Asa (bib1) 2022; 33 Gallo-Oller, Ordoñez, Dotor (bib78) 2018; 457 Liu, Hsu, Shen, Aslan, Stoyanova (bib79) 2022; 2472 Raman, Buongervino, Lane, Zhelev, Zhu, Cui, Martinez, Martinez, Wang, Upton (bib11) 2021; 2 Xu, Valerio, Eisold, Sinha, Koche, Hu, Chen, Chu, Brien, Park (bib66) 2016; 30 Mu, Zhang, Benelli, Karthaus, Hoover, Chen, Wongvipat, Ku, Gao, Cao (bib18) 2017; 355 Ku, Rosario, Wang, Mu, Seshadri, Goodrich, Goodrich, Labbé, Gomez, Wang (bib23) 2017; 355 Sakuma, Raices, Borlido, Guglielmi, Zhu, D'Angelo (bib64) 2021; 11 Ma, Li, Jia, Gong, Wang, Zhang, Gu, Tang (bib45) 2019; 10 Rohrbeck, Neukirchen, Rosskopf, Pardillos, Geddert, Schwalen, Gabbert, von Haeseler, Pitschke, Schott (bib74) 2008; 6 Corella, Cabiliza Ordonio, Coleman, Lucas, Kaipainen, Nguyen, Sondheim, Brown, True, Lee (bib6) 2020; 26 Beltran, Prandi, Mosquera, Benelli, Puca, Cyrta, Marotz, Giannopoulou, Chakravarthi, Varambally (bib50) 2016; 22 Tao, Mohammad, Milazzo, Moreno-Smith, Patel, Zorman, Badachhape, Hernandez, Wolf, Zeng (bib30) 2022; 13 Zugazagoitia, Paz-Ares (bib63) 2022; 40 Wei, Siegel, Aggarwal, Lin, Friedlander, Fong, Kim, Louttit, Chang, Zhang, Ryan (bib68) 2018; 23 Beltran, Rickman, Park, Chae, Sboner, MacDonald, Wang, Sheikh, Terry, Tagawa (bib28) 2011; 1 Smith, Sokolov, Uzunangelov, Baertsch, Newton, Graim, Mathis, Cheng, Stuart, Witte (bib31) 2015; 112 Jahchan, Dudley, Mazur, Flores, Yang, Palmerton, Zmoos, Vaka, Tran, Zhou (bib76) 2013; 3 Mondello, Kobeissy, Vestri, Hayes, Kochanek, Berger (bib36) 2016; 6 Liu, González-Prieto, Zhang, Geurink, Kooij, Iyengar, van Dinther, Bos, Zhang, Le Dévédec (bib33) 2020; 26 Zhao, Lei, He, Li, Wang, Hong, Liang, Li, Chen, Luo (bib60) 2020; 9 van Meerbeeck, Fennell, De Ruysscher (bib3) 2011; 378 Nadal (10.1016/j.xcrm.2023.101381_bib4) 2014; 11 Peifer (10.1016/j.xcrm.2023.101381_bib29) 2012; 44 Hsu (10.1016/j.xcrm.2023.101381_bib48) 2020; 117 Ghandi (10.1016/j.xcrm.2023.101381_bib53) 2019; 569 Rohrbeck (10.1016/j.xcrm.2023.101381_bib74) 2008; 6 Tan (10.1016/j.xcrm.2023.101381_bib17) 2014; 20 Bhattacharjee (10.1016/j.xcrm.2023.101381_bib51) 2001; 98 Seo (10.1016/j.xcrm.2023.101381_bib59) 2017; 137 Rindi (10.1016/j.xcrm.2023.101381_bib1) 2022; 33 Nachmias (10.1016/j.xcrm.2023.101381_bib69) 2020; 34 Hurst-Kennedy (10.1016/j.xcrm.2023.101381_bib57) 2012; 2012 Xu (10.1016/j.xcrm.2023.101381_bib66) 2016; 30 Hussain (10.1016/j.xcrm.2023.101381_bib37) 2018; 132 Amin (10.1016/j.xcrm.2023.101381_bib65) 2021; 12 Raman (10.1016/j.xcrm.2023.101381_bib11) 2021; 2 Liu (10.1016/j.xcrm.2023.101381_bib16) 2022; 86 Zhang (10.1016/j.xcrm.2023.101381_bib43) 2020; 24 Corella (10.1016/j.xcrm.2023.101381_bib6) 2020; 26 Mondello (10.1016/j.xcrm.2023.101381_bib36) 2016; 6 Gatto (10.1016/j.xcrm.2023.101381_bib80) 2012; 28 Wei (10.1016/j.xcrm.2023.101381_bib68) 2018; 23 Shimada (10.1016/j.xcrm.2023.101381_bib71) 2020; 111 Liu (10.1016/j.xcrm.2023.101381_bib58) 2002; 111 Guo (10.1016/j.xcrm.2023.101381_bib9) 2019; 10 Jiang (10.1016/j.xcrm.2023.101381_bib8) 2021; 13 Park (10.1016/j.xcrm.2023.101381_bib5) 2018; 362 Rudin (10.1016/j.xcrm.2023.101381_bib7) 2021; 7 Brady (10.1016/j.xcrm.2023.101381_bib24) 2021; 12 Liu (10.1016/j.xcrm.2023.101381_bib79) 2022; 2472 Wang (10.1016/j.xcrm.2023.101381_bib27) 2015; 113 Liu (10.1016/j.xcrm.2023.101381_bib61) 2003; 10 Schuller (10.1016/j.xcrm.2023.101381_bib41) 2021; 598 Balanis (10.1016/j.xcrm.2023.101381_bib49) 2019; 36 George (10.1016/j.xcrm.2023.101381_bib70) 2015; 524 Wang (10.1016/j.xcrm.2023.101381_bib44) 2020; 20 Abida (10.1016/j.xcrm.2023.101381_bib73) 2019; 116 Beck (10.1016/j.xcrm.2023.101381_bib40) 2017; 18 Halabi (10.1016/j.xcrm.2023.101381_bib52) 2016; 34 Almstedt (10.1016/j.xcrm.2023.101381_bib55) 2020; 11 Zugazagoitia (10.1016/j.xcrm.2023.101381_bib63) 2022; 40 Aslan (10.1016/j.xcrm.2023.101381_bib77) 2021; 6 Dechat (10.1016/j.xcrm.2023.101381_bib56) 2000; 129 Smith (10.1016/j.xcrm.2023.101381_bib31) 2015; 112 Knockenhauer (10.1016/j.xcrm.2023.101381_bib42) 2016; 164 Alabi (10.1016/j.xcrm.2023.101381_bib14) 2022; 238 Ma (10.1016/j.xcrm.2023.101381_bib45) 2019; 10 Nguyen (10.1016/j.xcrm.2023.101381_bib72) 2017; 77 Mu (10.1016/j.xcrm.2023.101381_bib18) 2017; 355 Qiu (10.1016/j.xcrm.2023.101381_bib12) 2022; 19 Panyain (10.1016/j.xcrm.2023.101381_bib62) 2020; 142 Jahchan (10.1016/j.xcrm.2023.101381_bib76) 2013; 3 Garber (10.1016/j.xcrm.2023.101381_bib75) 2001; 98 Chen (10.1016/j.xcrm.2023.101381_bib21) 2018; 128 Sakuma (10.1016/j.xcrm.2023.101381_bib64) 2021; 11 Pinto (10.1016/j.xcrm.2023.101381_bib13) 2015; 33 DeRose (10.1016/j.xcrm.2023.101381_bib82) 2013 Rodriguez-Bravo (10.1016/j.xcrm.2023.101381_bib47) 2018; 174 Kim (10.1016/j.xcrm.2023.101381_bib26) 2021; 27 Hussain (10.1016/j.xcrm.2023.101381_bib38) 2010; 24 Yin (10.1016/j.xcrm.2023.101381_bib25) 2019; 18 Tao (10.1016/j.xcrm.2023.101381_bib30) 2022; 13 Gallo-Oller (10.1016/j.xcrm.2023.101381_bib78) 2018; 457 Bi (10.1016/j.xcrm.2023.101381_bib32) 2020; 6 Lassman (10.1016/j.xcrm.2023.101381_bib67) 2022; 28 Zhong (10.1016/j.xcrm.2023.101381_bib39) 2012; 30 Ku (10.1016/j.xcrm.2023.101381_bib23) 2017; 355 Zhang (10.1016/j.xcrm.2023.101381_bib20) 2018; 9 Luo (10.1016/j.xcrm.2023.101381_bib19) 2019; 10 Navarro (10.1016/j.xcrm.2023.101381_bib81) 2014; 13 Bishop (10.1016/j.xcrm.2023.101381_bib22) 2017; 7 Beltran (10.1016/j.xcrm.2023.101381_bib28) 2011; 1 Beltran (10.1016/j.xcrm.2023.101381_bib50) 2016; 22 Liu (10.1016/j.xcrm.2023.101381_bib54) 2019; 25 Zhao (10.1016/j.xcrm.2023.101381_bib60) 2020; 9 Mondello (10.1016/j.xcrm.2023.101381_bib35) 2012; 70 Guan (10.1016/j.xcrm.2023.101381_bib46) 2021; 32 Petty (10.1016/j.xcrm.2023.101381_bib15) 2023; 9 Li (10.1016/j.xcrm.2023.101381_bib34) 2010; 16 Liu (10.1016/j.xcrm.2023.101381_bib33) 2020; 26 Sarbassov (10.1016/j.xcrm.2023.101381_bib83) 2005; 307 Maris (10.1016/j.xcrm.2023.101381_bib2) 2010; 362 van Meerbeeck (10.1016/j.xcrm.2023.101381_bib3) 2011; 378 Unno (10.1016/j.xcrm.2023.101381_bib10) 2021; 81 |
References_xml | – volume: 20 start-page: 345 year: 2020 end-page: 353 ident: bib44 article-title: POM121 overexpression is related to a poor prognosis in colorectal cancer publication-title: Expert Rev. Mol. Diagn. contributor: fullname: Jia – volume: 77 start-page: 654 year: 2017 end-page: 671 ident: bib72 article-title: LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics publication-title: Prostate contributor: fullname: Lam – volume: 16 start-page: 2949 year: 2010 end-page: 2958 ident: bib34 article-title: The tumor suppressor UCHL1 forms a complex with p53/MDM2/ARF to promote p53 signaling and is frequently silenced in nasopharyngeal carcinoma publication-title: Clin. Cancer Res. contributor: fullname: Cao – volume: 9 start-page: 419 year: 2023 end-page: 429 ident: bib15 article-title: Emerging Strategies for the Treatment of Small Cell Lung Cancer: A Review publication-title: JAMA Oncol. contributor: fullname: Paz-Ares – volume: 111 start-page: 209 year: 2002 end-page: 218 ident: bib58 article-title: The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility publication-title: Cell contributor: fullname: Lansbury – volume: 2 year: 2021 ident: bib11 article-title: A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope publication-title: Cell Rep. Med. contributor: fullname: Upton – volume: 117 start-page: 2032 year: 2020 end-page: 2042 ident: bib48 article-title: Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1 publication-title: Proc. Natl. Acad. Sci. USA contributor: fullname: Zlitni – volume: 34 start-page: 1652 year: 2016 end-page: 1659 ident: bib52 article-title: Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer publication-title: J. Clin. Oncol. contributor: fullname: Hussain – volume: 11 start-page: 176 year: 2021 end-page: 193 ident: bib64 article-title: Inhibition of Nuclear Pore Complex Formation Selectively Induces Cancer Cell Death publication-title: Cancer Discov. contributor: fullname: D'Angelo – volume: 1 start-page: 487 year: 2011 end-page: 495 ident: bib28 article-title: Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets publication-title: Cancer Discov. contributor: fullname: Tagawa – volume: 355 start-page: 78 year: 2017 end-page: 83 ident: bib23 article-title: Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance publication-title: Science contributor: fullname: Wang – volume: 20 start-page: 890 year: 2014 end-page: 903 ident: bib17 article-title: Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma publication-title: Clin. Cancer Res. contributor: fullname: Netto – volume: 238 year: 2022 ident: bib14 article-title: Current and emerging therapies for neuroendocrine prostate cancer publication-title: Pharmacol. Ther. contributor: fullname: Stoyanova – volume: 25 start-page: 6839 year: 2019 end-page: 6851 ident: bib54 article-title: PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer publication-title: Clin. Cancer Res. contributor: fullname: Tang – volume: 113 start-page: 57 year: 2015 end-page: 63 ident: bib27 article-title: Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study publication-title: Br. J. Cancer contributor: fullname: Park – volume: 13 year: 2021 ident: bib8 article-title: Targeting netrin-3 in small cell lung cancer and neuroblastoma publication-title: EMBO Mol. Med. contributor: fullname: Hervieu – volume: 378 start-page: 1741 year: 2011 end-page: 1755 ident: bib3 article-title: Small-cell lung cancer publication-title: Lancet contributor: fullname: De Ruysscher – volume: 3 start-page: 1364 year: 2013 end-page: 1377 ident: bib76 article-title: A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors publication-title: Cancer Discov. contributor: fullname: Zhou – volume: 9 start-page: 4080 year: 2018 ident: bib20 article-title: Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancers publication-title: Nat. Commun. contributor: fullname: Ittmann – volume: 7 start-page: 54 year: 2017 end-page: 71 ident: bib22 article-title: The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer publication-title: Cancer Discov. contributor: fullname: Johnson – volume: 12 start-page: 3372 year: 2021 ident: bib24 article-title: Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer publication-title: Nat. Commun. contributor: fullname: Bakht – volume: 9 start-page: 559 year: 2020 ident: bib60 article-title: Hypermethylation of UCHL1 Promotes Metastasis of Nasopharyngeal Carcinoma by Suppressing Degradation of Cortactin (CTTN) publication-title: Cells contributor: fullname: Luo – volume: 11 start-page: 213 year: 2014 end-page: 219 ident: bib4 article-title: Small cell carcinoma of the prostate publication-title: Nat. Rev. Urol. contributor: fullname: Eisenberger – volume: 27 start-page: 4923 year: 2021 end-page: 4936 ident: bib26 article-title: BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program publication-title: Clin. Cancer Res. contributor: fullname: Rodansky – volume: 13 start-page: 3728 year: 2022 ident: bib30 article-title: MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma publication-title: Nat. Commun. contributor: fullname: Zeng – volume: 6 year: 2016 ident: bib36 article-title: Serum Concentrations of Ubiquitin C-Terminal Hydrolase-L1 and Glial Fibrillary Acidic Protein after Pediatric Traumatic Brain Injury publication-title: Sci. Rep. contributor: fullname: Berger – volume: 19 start-page: 515 year: 2022 end-page: 533 ident: bib12 article-title: Advancing therapy for neuroblastoma publication-title: Nat. Rev. Clin. Oncol. contributor: fullname: Matthay – volume: 24 start-page: 1641 year: 2010 end-page: 1655 ident: bib38 article-title: The de-ubiquitinase UCH-L1 is an oncogene that drives the development of lymphoma in vivo by deregulating PHLPP1 and Akt signaling publication-title: Leukemia contributor: fullname: Galardy – volume: 70 start-page: 666 year: 2012 end-page: 675 ident: bib35 article-title: Clinical utility of serum levels of ubiquitin C-terminal hydrolase as a biomarker for severe traumatic brain injury publication-title: Neurosurgery contributor: fullname: Wang – volume: 307 start-page: 1098 year: 2005 end-page: 1101 ident: bib83 article-title: Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex publication-title: Science contributor: fullname: Sabatini – year: 2013 ident: bib82 article-title: Patient-derived models of human breast cancer: protocols for in vitro and in vivo applications in tumor biology and translational medicine. publication-title: In Curr Protoc Pharmacol. contributor: fullname: Welm – volume: 164 start-page: 1162 year: 2016 end-page: 1171 ident: bib42 article-title: The Nuclear Pore Complex as a Flexible and Dynamic Gate publication-title: Cell contributor: fullname: Schwartz – volume: 137 start-page: 1757 year: 2017 end-page: 1765 ident: bib59 article-title: UCHL1 Regulates Melanogenesis through Controlling MITF Stability in Human Melanocytes publication-title: J. Invest. Dermatol. contributor: fullname: Chung – volume: 34 start-page: 2875 year: 2020 end-page: 2886 ident: bib69 article-title: Targeting nuclear import and export in hematological malignancies publication-title: Leukemia contributor: fullname: Schimmer – volume: 86 start-page: 57 year: 2022 end-page: 68 ident: bib16 article-title: Molecular mechanisms underlying the development of neuroendocrine prostate cancer publication-title: Semin. Cancer Biol. contributor: fullname: Stoyanova – volume: 362 start-page: 91 year: 2018 end-page: 95 ident: bib5 article-title: Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage publication-title: Science contributor: fullname: Cheng – volume: 33 start-page: 3008 year: 2015 end-page: 3017 ident: bib13 article-title: Advances in Risk Classification and Treatment Strategies for Neuroblastoma publication-title: J. Clin. Oncol. contributor: fullname: Park – volume: 6 start-page: 69 year: 2008 ident: bib74 article-title: Gene expression profiling for molecular distinction and characterization of laser captured primary lung cancers publication-title: J. Transl. Med. contributor: fullname: Schott – volume: 28 start-page: 288 year: 2012 end-page: 289 ident: bib80 article-title: MSnbase-an R/Bioconductor package for isobaric tagged mass spectrometry data visualization, processing and quantitation publication-title: Bioinformatics contributor: fullname: Lilley – volume: 2012 year: 2012 ident: bib57 article-title: Ubiquitin C-terminal hydrolase l1 in tumorigenesis publication-title: Biochem. Res. Int. contributor: fullname: Li – volume: 174 start-page: 1200 year: 2018 end-page: 1215.e20 ident: bib47 article-title: Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import publication-title: Cell contributor: fullname: Lokareddy – volume: 23 start-page: 656 year: 2018 end-page: e64 ident: bib68 article-title: A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer publication-title: Oncol. contributor: fullname: Ryan – volume: 33 start-page: 115 year: 2022 end-page: 154 ident: bib1 article-title: Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms publication-title: Endocr. Pathol. contributor: fullname: Asa – volume: 355 start-page: 84 year: 2017 end-page: 88 ident: bib18 article-title: SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer publication-title: Science contributor: fullname: Cao – volume: 22 start-page: 298 year: 2016 end-page: 305 ident: bib50 article-title: Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer publication-title: Nat. Med. contributor: fullname: Varambally – volume: 569 start-page: 503 year: 2019 end-page: 508 ident: bib53 article-title: Next-generation characterization of the Cancer Cell Line Encyclopedia publication-title: Nature contributor: fullname: Li – volume: 30 start-page: 430 year: 2012 end-page: 436 ident: bib39 article-title: UCHL1 acts as a colorectal cancer oncogene via activation of the beta-catenin/TCF pathway through its deubiquitinating activity publication-title: Int. J. Mol. Med. contributor: fullname: Huang – volume: 116 start-page: 11428 year: 2019 end-page: 11436 ident: bib73 article-title: Genomic correlates of clinical outcome in advanced prostate cancer publication-title: Proc. Natl. Acad. Sci. USA contributor: fullname: Van Allen – volume: 10 start-page: 278 year: 2019 ident: bib9 article-title: ONECUT2 is a driver of neuroendocrine prostate cancer publication-title: Nat. Commun. contributor: fullname: Li – volume: 132 start-page: 2564 year: 2018 end-page: 2574 ident: bib37 article-title: UCH-L1 bypasses mTOR to promote protein biosynthesis and is required for MYC-driven lymphomagenesis in mice publication-title: Blood contributor: fullname: Galardy – volume: 11 start-page: 71 year: 2020 ident: bib55 article-title: Integrative discovery of treatments for high-risk neuroblastoma publication-title: Nat. Commun. contributor: fullname: Sundström – volume: 111 start-page: 610 year: 2020 end-page: 620 ident: bib71 article-title: Ubiquitin C-terminal hydrolase-L1 has prognostic relevance and is a therapeutic target for high-grade neuroendocrine lung cancers publication-title: Cancer Sci. contributor: fullname: Ikeda – volume: 12 start-page: 7216 year: 2021 ident: bib65 article-title: Nuclear pore protein NUP210 depletion suppresses metastasis through heterochromatin-mediated disruption of tumor cell mechanical response publication-title: Nat. Commun. contributor: fullname: Burkett – volume: 10 start-page: 2571 year: 2019 ident: bib19 article-title: LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling publication-title: Nat. Commun. contributor: fullname: Maity – volume: 598 start-page: 667 year: 2021 end-page: 671 ident: bib41 article-title: The cellular environment shapes the nuclear pore complex architecture publication-title: Nature contributor: fullname: Dasso – volume: 26 start-page: 1667 year: 2020 end-page: 1677 ident: bib6 article-title: Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer publication-title: Clin. Cancer Res. contributor: fullname: Lee – volume: 44 start-page: 1104 year: 2012 end-page: 1110 ident: bib29 article-title: Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer publication-title: Nat. Genet. contributor: fullname: Zander – volume: 18 start-page: 73 year: 2017 end-page: 89 ident: bib40 article-title: The nuclear pore complex: understanding its function through structural insight publication-title: Nat. Rev. Mol. Cell Biol. contributor: fullname: Hurt – volume: 18 start-page: 11 year: 2019 ident: bib25 article-title: N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway publication-title: Mol. Cancer contributor: fullname: Huang – volume: 81 start-page: 2157 year: 2021 end-page: 2170 ident: bib10 article-title: Activated ALK Cooperates with N-Myc via Wnt/beta-Catenin Signaling to Induce Neuroendocrine Prostate Cancer publication-title: Cancer Res. contributor: fullname: Yoo – volume: 24 start-page: 819 year: 2020 end-page: 824 ident: bib43 article-title: Clinical Significance of POM121 Expression in Lung Cancer publication-title: Genet. Test. Mol. Biomarkers contributor: fullname: Tan – volume: 26 start-page: 1460 year: 2020 end-page: 1473 ident: bib33 article-title: Deubiquitinase Activity Profiling Identifies UCHL1 as a Candidate Oncoprotein That Promotes TGFbeta-Induced Breast Cancer Metastasis publication-title: Clin. Cancer Res. contributor: fullname: Le Dévédec – volume: 6 start-page: bpab014 year: 2021 ident: bib77 article-title: Quantifying the invasion and migration ability of cancer cells with a 3D Matrigel drop invasion assay publication-title: Biol. Methods Protoc. contributor: fullname: Stoyanova – volume: 142 start-page: 12020 year: 2020 end-page: 12026 ident: bib62 article-title: Discovery of a Potent and Selective Covalent Inhibitor and Activity-Based Probe for the Deubiquitylating Enzyme UCHL1, with Antifibrotic Activity publication-title: J. Am. Chem. Soc. contributor: fullname: Smith – volume: 98 start-page: 13790 year: 2001 end-page: 13795 ident: bib51 article-title: Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses publication-title: Proc. Natl. Acad. Sci. USA contributor: fullname: Gillette – volume: 129 start-page: 335 year: 2000 end-page: 345 ident: bib56 article-title: Review: lamina-associated polypeptide 2 isoforms and related proteins in cell cycle-dependent nuclear structure dynamics publication-title: J. Struct. Biol. contributor: fullname: Foisner – volume: 524 start-page: 47 year: 2015 end-page: 53 ident: bib70 article-title: Comprehensive genomic profiles of small cell lung cancer publication-title: Nature contributor: fullname: Bosco – volume: 10 start-page: 4473 year: 2019 end-page: 4480 ident: bib45 article-title: POM121 is identified as a novel prognostic marker of oral squamous cell carcinoma publication-title: J. Cancer contributor: fullname: Tang – volume: 457 start-page: 1 year: 2018 end-page: 5 ident: bib78 article-title: A new background subtraction method for Western blot densitometry band quantification through image analysis software publication-title: J. Immunol. Methods contributor: fullname: Dotor – volume: 112 start-page: E6544 year: 2015 end-page: E6552 ident: bib31 article-title: A basal stem cell signature identifies aggressive prostate cancer phenotypes publication-title: Proc. Natl. Acad. Sci. USA contributor: fullname: Witte – volume: 98 start-page: 13784 year: 2001 end-page: 13789 ident: bib75 article-title: Diversity of gene expression in adenocarcinoma of the lung publication-title: Proc. Natl. Acad. Sci. USA contributor: fullname: Whyte – volume: 30 start-page: 863 year: 2016 end-page: 878 ident: bib66 article-title: NUP98 Fusion Proteins Interact with the NSL and MLL1 Complexes to Drive Leukemogenesis publication-title: Cancer Cell contributor: fullname: Park – volume: 13 start-page: 1234 year: 2014 end-page: 1247 ident: bib81 article-title: General statistical framework for quantitative proteomics by stable isotope labeling publication-title: J. Proteome Res. contributor: fullname: Carrascal – volume: 28 start-page: 452 year: 2022 end-page: 460 ident: bib67 article-title: A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma publication-title: Clin. Cancer Res. contributor: fullname: Tamir – volume: 36 start-page: 17 year: 2019 end-page: 34.e7 ident: bib49 article-title: Pan-cancer Convergence to a Small-Cell Neuroendocrine Phenotype that Shares Susceptibilities with Hematological Malignancies publication-title: Cancer Cell contributor: fullname: Graeber – volume: 2472 start-page: 221 year: 2022 end-page: 233 ident: bib79 article-title: Metastasis Model to Test the Role of Notch Signaling in Prostate Cancer publication-title: Methods Mol. Biol. contributor: fullname: Stoyanova – volume: 10 start-page: 837 year: 2003 end-page: 846 ident: bib61 article-title: Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line publication-title: Chem. Biol. contributor: fullname: Lansbury – volume: 32 start-page: 293 year: 2021 end-page: 302 ident: bib46 article-title: POM121 promotes proliferation and metastasis in non-small-cell lung cancer through TGF-beta/SMAD and PI3K/AKT pathways publication-title: Cancer Biomark. contributor: fullname: Zhao – volume: 6 year: 2020 ident: bib32 article-title: The deubiquitinase UCHL1 regulates cardiac hypertrophy by stabilizing epidermal growth factor receptor publication-title: Sci. Adv. contributor: fullname: Li – volume: 40 start-page: 671 year: 2022 end-page: 680 ident: bib63 article-title: Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options publication-title: J. Clin. Oncol. contributor: fullname: Paz-Ares – volume: 362 start-page: 2202 year: 2010 end-page: 2211 ident: bib2 article-title: Recent advances in neuroblastoma publication-title: N. Engl. J. Med. contributor: fullname: Maris – volume: 128 start-page: 446 year: 2018 end-page: 462 ident: bib21 article-title: CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2 publication-title: J. Clin. Invest. contributor: fullname: Qi – volume: 7 start-page: 3 year: 2021 ident: bib7 article-title: Small-cell lung cancer publication-title: Nat. Rev. Dis. Primers contributor: fullname: Sage – volume: 13 start-page: 3728 year: 2022 ident: 10.1016/j.xcrm.2023.101381_bib30 article-title: MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma publication-title: Nat. Commun. doi: 10.1038/s41467-022-31331-2 contributor: fullname: Tao – volume: 137 start-page: 1757 year: 2017 ident: 10.1016/j.xcrm.2023.101381_bib59 article-title: UCHL1 Regulates Melanogenesis through Controlling MITF Stability in Human Melanocytes publication-title: J. Invest. Dermatol. doi: 10.1016/j.jid.2017.03.024 contributor: fullname: Seo – volume: 20 start-page: 890 year: 2014 ident: 10.1016/j.xcrm.2023.101381_bib17 article-title: Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-13-1982 contributor: fullname: Tan – volume: 40 start-page: 671 year: 2022 ident: 10.1016/j.xcrm.2023.101381_bib63 article-title: Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options publication-title: J. Clin. Oncol. doi: 10.1200/JCO.21.01881 contributor: fullname: Zugazagoitia – volume: 362 start-page: 2202 year: 2010 ident: 10.1016/j.xcrm.2023.101381_bib2 article-title: Recent advances in neuroblastoma publication-title: N. Engl. J. Med. doi: 10.1056/NEJMra0804577 contributor: fullname: Maris – volume: 6 year: 2016 ident: 10.1016/j.xcrm.2023.101381_bib36 article-title: Serum Concentrations of Ubiquitin C-Terminal Hydrolase-L1 and Glial Fibrillary Acidic Protein after Pediatric Traumatic Brain Injury publication-title: Sci. Rep. doi: 10.1038/srep28203 contributor: fullname: Mondello – volume: 16 start-page: 2949 year: 2010 ident: 10.1016/j.xcrm.2023.101381_bib34 article-title: The tumor suppressor UCHL1 forms a complex with p53/MDM2/ARF to promote p53 signaling and is frequently silenced in nasopharyngeal carcinoma publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-09-3178 contributor: fullname: Li – volume: 9 start-page: 419 year: 2023 ident: 10.1016/j.xcrm.2023.101381_bib15 article-title: Emerging Strategies for the Treatment of Small Cell Lung Cancer: A Review publication-title: JAMA Oncol. doi: 10.1001/jamaoncol.2022.5631 contributor: fullname: Petty – volume: 111 start-page: 610 year: 2020 ident: 10.1016/j.xcrm.2023.101381_bib71 article-title: Ubiquitin C-terminal hydrolase-L1 has prognostic relevance and is a therapeutic target for high-grade neuroendocrine lung cancers publication-title: Cancer Sci. doi: 10.1111/cas.14284 contributor: fullname: Shimada – volume: 362 start-page: 91 year: 2018 ident: 10.1016/j.xcrm.2023.101381_bib5 article-title: Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage publication-title: Science doi: 10.1126/science.aat5749 contributor: fullname: Park – volume: 23 start-page: 656 year: 2018 ident: 10.1016/j.xcrm.2023.101381_bib68 article-title: A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer publication-title: Oncol. doi: 10.1634/theoncologist.2017-0624 contributor: fullname: Wei – volume: 116 start-page: 11428 year: 2019 ident: 10.1016/j.xcrm.2023.101381_bib73 article-title: Genomic correlates of clinical outcome in advanced prostate cancer publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.1902651116 contributor: fullname: Abida – volume: 10 start-page: 278 year: 2019 ident: 10.1016/j.xcrm.2023.101381_bib9 article-title: ONECUT2 is a driver of neuroendocrine prostate cancer publication-title: Nat. Commun. doi: 10.1038/s41467-018-08133-6 contributor: fullname: Guo – volume: 28 start-page: 452 year: 2022 ident: 10.1016/j.xcrm.2023.101381_bib67 article-title: A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-21-2225 contributor: fullname: Lassman – volume: 33 start-page: 115 year: 2022 ident: 10.1016/j.xcrm.2023.101381_bib1 article-title: Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms publication-title: Endocr. Pathol. doi: 10.1007/s12022-022-09708-2 contributor: fullname: Rindi – volume: 524 start-page: 47 year: 2015 ident: 10.1016/j.xcrm.2023.101381_bib70 article-title: Comprehensive genomic profiles of small cell lung cancer publication-title: Nature doi: 10.1038/nature14664 contributor: fullname: George – volume: 1 start-page: 487 year: 2011 ident: 10.1016/j.xcrm.2023.101381_bib28 article-title: Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-11-0130 contributor: fullname: Beltran – volume: 6 year: 2020 ident: 10.1016/j.xcrm.2023.101381_bib32 article-title: The deubiquitinase UCHL1 regulates cardiac hypertrophy by stabilizing epidermal growth factor receptor publication-title: Sci. Adv. doi: 10.1126/sciadv.aax4826 contributor: fullname: Bi – volume: 32 start-page: 293 year: 2021 ident: 10.1016/j.xcrm.2023.101381_bib46 article-title: POM121 promotes proliferation and metastasis in non-small-cell lung cancer through TGF-beta/SMAD and PI3K/AKT pathways publication-title: Cancer Biomark. doi: 10.3233/CBM-210001 contributor: fullname: Guan – volume: 569 start-page: 503 year: 2019 ident: 10.1016/j.xcrm.2023.101381_bib53 article-title: Next-generation characterization of the Cancer Cell Line Encyclopedia publication-title: Nature doi: 10.1038/s41586-019-1186-3 contributor: fullname: Ghandi – volume: 10 start-page: 4473 year: 2019 ident: 10.1016/j.xcrm.2023.101381_bib45 article-title: POM121 is identified as a novel prognostic marker of oral squamous cell carcinoma publication-title: J. Cancer doi: 10.7150/jca.33368 contributor: fullname: Ma – volume: 111 start-page: 209 year: 2002 ident: 10.1016/j.xcrm.2023.101381_bib58 article-title: The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility publication-title: Cell doi: 10.1016/S0092-8674(02)01012-7 contributor: fullname: Liu – volume: 28 start-page: 288 year: 2012 ident: 10.1016/j.xcrm.2023.101381_bib80 article-title: MSnbase-an R/Bioconductor package for isobaric tagged mass spectrometry data visualization, processing and quantitation publication-title: Bioinformatics doi: 10.1093/bioinformatics/btr645 contributor: fullname: Gatto – volume: 129 start-page: 335 year: 2000 ident: 10.1016/j.xcrm.2023.101381_bib56 article-title: Review: lamina-associated polypeptide 2 isoforms and related proteins in cell cycle-dependent nuclear structure dynamics publication-title: J. Struct. Biol. doi: 10.1006/jsbi.2000.4212 contributor: fullname: Dechat – volume: 86 start-page: 57 year: 2022 ident: 10.1016/j.xcrm.2023.101381_bib16 article-title: Molecular mechanisms underlying the development of neuroendocrine prostate cancer publication-title: Semin. Cancer Biol. doi: 10.1016/j.semcancer.2022.05.007 contributor: fullname: Liu – volume: 164 start-page: 1162 year: 2016 ident: 10.1016/j.xcrm.2023.101381_bib42 article-title: The Nuclear Pore Complex as a Flexible and Dynamic Gate publication-title: Cell doi: 10.1016/j.cell.2016.01.034 contributor: fullname: Knockenhauer – volume: 7 start-page: 54 year: 2017 ident: 10.1016/j.xcrm.2023.101381_bib22 article-title: The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-15-1263 contributor: fullname: Bishop – volume: 81 start-page: 2157 year: 2021 ident: 10.1016/j.xcrm.2023.101381_bib10 article-title: Activated ALK Cooperates with N-Myc via Wnt/beta-Catenin Signaling to Induce Neuroendocrine Prostate Cancer publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-20-3351 contributor: fullname: Unno – volume: 128 start-page: 446 year: 2018 ident: 10.1016/j.xcrm.2023.101381_bib21 article-title: CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2 publication-title: J. Clin. Invest. doi: 10.1172/JCI90793 contributor: fullname: Chen – volume: 22 start-page: 298 year: 2016 ident: 10.1016/j.xcrm.2023.101381_bib50 article-title: Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer publication-title: Nat. Med. doi: 10.1038/nm.4045 contributor: fullname: Beltran – volume: 238 year: 2022 ident: 10.1016/j.xcrm.2023.101381_bib14 article-title: Current and emerging therapies for neuroendocrine prostate cancer publication-title: Pharmacol. Ther. doi: 10.1016/j.pharmthera.2022.108255 contributor: fullname: Alabi – volume: 34 start-page: 2875 year: 2020 ident: 10.1016/j.xcrm.2023.101381_bib69 article-title: Targeting nuclear import and export in hematological malignancies publication-title: Leukemia doi: 10.1038/s41375-020-0958-y contributor: fullname: Nachmias – volume: 98 start-page: 13790 year: 2001 ident: 10.1016/j.xcrm.2023.101381_bib51 article-title: Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.191502998 contributor: fullname: Bhattacharjee – volume: 378 start-page: 1741 year: 2011 ident: 10.1016/j.xcrm.2023.101381_bib3 article-title: Small-cell lung cancer publication-title: Lancet doi: 10.1016/S0140-6736(11)60165-7 contributor: fullname: van Meerbeeck – volume: 70 start-page: 666 year: 2012 ident: 10.1016/j.xcrm.2023.101381_bib35 article-title: Clinical utility of serum levels of ubiquitin C-terminal hydrolase as a biomarker for severe traumatic brain injury publication-title: Neurosurgery contributor: fullname: Mondello – volume: 598 start-page: 667 year: 2021 ident: 10.1016/j.xcrm.2023.101381_bib41 article-title: The cellular environment shapes the nuclear pore complex architecture publication-title: Nature doi: 10.1038/s41586-021-03985-3 contributor: fullname: Schuller – volume: 36 start-page: 17 year: 2019 ident: 10.1016/j.xcrm.2023.101381_bib49 article-title: Pan-cancer Convergence to a Small-Cell Neuroendocrine Phenotype that Shares Susceptibilities with Hematological Malignancies publication-title: Cancer Cell doi: 10.1016/j.ccell.2019.06.005 contributor: fullname: Balanis – volume: 307 start-page: 1098 year: 2005 ident: 10.1016/j.xcrm.2023.101381_bib83 article-title: Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex publication-title: Science doi: 10.1126/science.1106148 contributor: fullname: Sarbassov – volume: 3 start-page: 1364 year: 2013 ident: 10.1016/j.xcrm.2023.101381_bib76 article-title: A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-13-0183 contributor: fullname: Jahchan – volume: 355 start-page: 84 year: 2017 ident: 10.1016/j.xcrm.2023.101381_bib18 article-title: SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer publication-title: Science doi: 10.1126/science.aah4307 contributor: fullname: Mu – volume: 174 start-page: 1200 year: 2018 ident: 10.1016/j.xcrm.2023.101381_bib47 article-title: Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import publication-title: Cell doi: 10.1016/j.cell.2018.07.015 contributor: fullname: Rodriguez-Bravo – volume: 13 start-page: 1234 year: 2014 ident: 10.1016/j.xcrm.2023.101381_bib81 article-title: General statistical framework for quantitative proteomics by stable isotope labeling publication-title: J. Proteome Res. doi: 10.1021/pr4006958 contributor: fullname: Navarro – volume: 25 start-page: 6839 year: 2019 ident: 10.1016/j.xcrm.2023.101381_bib54 article-title: PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-19-0317 contributor: fullname: Liu – volume: 117 start-page: 2032 year: 2020 ident: 10.1016/j.xcrm.2023.101381_bib48 article-title: Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1 publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.1905384117 contributor: fullname: Hsu – volume: 142 start-page: 12020 year: 2020 ident: 10.1016/j.xcrm.2023.101381_bib62 article-title: Discovery of a Potent and Selective Covalent Inhibitor and Activity-Based Probe for the Deubiquitylating Enzyme UCHL1, with Antifibrotic Activity publication-title: J. Am. Chem. Soc. doi: 10.1021/jacs.0c04527 contributor: fullname: Panyain – volume: 26 start-page: 1460 year: 2020 ident: 10.1016/j.xcrm.2023.101381_bib33 article-title: Deubiquitinase Activity Profiling Identifies UCHL1 as a Candidate Oncoprotein That Promotes TGFbeta-Induced Breast Cancer Metastasis publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-19-1373 contributor: fullname: Liu – volume: 12 start-page: 7216 year: 2021 ident: 10.1016/j.xcrm.2023.101381_bib65 article-title: Nuclear pore protein NUP210 depletion suppresses metastasis through heterochromatin-mediated disruption of tumor cell mechanical response publication-title: Nat. Commun. doi: 10.1038/s41467-021-27451-w contributor: fullname: Amin – volume: 11 start-page: 176 year: 2021 ident: 10.1016/j.xcrm.2023.101381_bib64 article-title: Inhibition of Nuclear Pore Complex Formation Selectively Induces Cancer Cell Death publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-20-0581 contributor: fullname: Sakuma – volume: 6 start-page: 69 year: 2008 ident: 10.1016/j.xcrm.2023.101381_bib74 article-title: Gene expression profiling for molecular distinction and characterization of laser captured primary lung cancers publication-title: J. Transl. Med. doi: 10.1186/1479-5876-6-69 contributor: fullname: Rohrbeck – volume: 10 start-page: 2571 year: 2019 ident: 10.1016/j.xcrm.2023.101381_bib19 article-title: LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling publication-title: Nat. Commun. doi: 10.1038/s41467-019-09784-9 contributor: fullname: Luo – volume: 112 start-page: E6544 year: 2015 ident: 10.1016/j.xcrm.2023.101381_bib31 article-title: A basal stem cell signature identifies aggressive prostate cancer phenotypes publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.1518007112 contributor: fullname: Smith – volume: 24 start-page: 819 year: 2020 ident: 10.1016/j.xcrm.2023.101381_bib43 article-title: Clinical Significance of POM121 Expression in Lung Cancer publication-title: Genet. Test. Mol. Biomarkers doi: 10.1089/gtmb.2020.0053 contributor: fullname: Zhang – volume: 2012 year: 2012 ident: 10.1016/j.xcrm.2023.101381_bib57 article-title: Ubiquitin C-terminal hydrolase l1 in tumorigenesis publication-title: Biochem. Res. Int. doi: 10.1155/2012/123706 contributor: fullname: Hurst-Kennedy – volume: 98 start-page: 13784 year: 2001 ident: 10.1016/j.xcrm.2023.101381_bib75 article-title: Diversity of gene expression in adenocarcinoma of the lung publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.241500798 contributor: fullname: Garber – volume: 12 start-page: 3372 year: 2021 ident: 10.1016/j.xcrm.2023.101381_bib24 article-title: Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer publication-title: Nat. Commun. doi: 10.1038/s41467-021-23780-y contributor: fullname: Brady – volume: 10 start-page: 837 year: 2003 ident: 10.1016/j.xcrm.2023.101381_bib61 article-title: Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line publication-title: Chem. Biol. doi: 10.1016/j.chembiol.2003.08.010 contributor: fullname: Liu – volume: 2 year: 2021 ident: 10.1016/j.xcrm.2023.101381_bib11 article-title: A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope publication-title: Cell Rep. Med. contributor: fullname: Raman – volume: 9 start-page: 4080 year: 2018 ident: 10.1016/j.xcrm.2023.101381_bib20 article-title: Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancers publication-title: Nat. Commun. doi: 10.1038/s41467-018-06177-2 contributor: fullname: Zhang – volume: 27 start-page: 4923 year: 2021 ident: 10.1016/j.xcrm.2023.101381_bib26 article-title: BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-20-4968 contributor: fullname: Kim – volume: 19 start-page: 515 year: 2022 ident: 10.1016/j.xcrm.2023.101381_bib12 article-title: Advancing therapy for neuroblastoma publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/s41571-022-00643-z contributor: fullname: Qiu – volume: 18 start-page: 73 year: 2017 ident: 10.1016/j.xcrm.2023.101381_bib40 article-title: The nuclear pore complex: understanding its function through structural insight publication-title: Nat. Rev. Mol. Cell Biol. doi: 10.1038/nrm.2016.147 contributor: fullname: Beck – volume: 20 start-page: 345 year: 2020 ident: 10.1016/j.xcrm.2023.101381_bib44 article-title: POM121 overexpression is related to a poor prognosis in colorectal cancer publication-title: Expert Rev. Mol. Diagn. doi: 10.1080/14737159.2020.1707670 contributor: fullname: Wang – volume: 26 start-page: 1667 year: 2020 ident: 10.1016/j.xcrm.2023.101381_bib6 article-title: Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-19-0775 contributor: fullname: Corella – volume: 457 start-page: 1 year: 2018 ident: 10.1016/j.xcrm.2023.101381_bib78 article-title: A new background subtraction method for Western blot densitometry band quantification through image analysis software publication-title: J. Immunol. Methods doi: 10.1016/j.jim.2018.03.004 contributor: fullname: Gallo-Oller – volume: 6 start-page: bpab014 year: 2021 ident: 10.1016/j.xcrm.2023.101381_bib77 article-title: Quantifying the invasion and migration ability of cancer cells with a 3D Matrigel drop invasion assay publication-title: Biol. Methods Protoc. doi: 10.1093/biomethods/bpab014 contributor: fullname: Aslan – volume: 355 start-page: 78 year: 2017 ident: 10.1016/j.xcrm.2023.101381_bib23 article-title: Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance publication-title: Science doi: 10.1126/science.aah4199 contributor: fullname: Ku – volume: 13 year: 2021 ident: 10.1016/j.xcrm.2023.101381_bib8 article-title: Targeting netrin-3 in small cell lung cancer and neuroblastoma publication-title: EMBO Mol. Med. doi: 10.15252/emmm.202012878 contributor: fullname: Jiang – volume: 113 start-page: 57 year: 2015 ident: 10.1016/j.xcrm.2023.101381_bib27 article-title: Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study publication-title: Br. J. Cancer doi: 10.1038/bjc.2015.188 contributor: fullname: Wang – volume: 18 start-page: 11 year: 2019 ident: 10.1016/j.xcrm.2023.101381_bib25 article-title: N-Myc promotes therapeutic resistance development of neuroendocrine prostate cancer by differentially regulating miR-421/ATM pathway publication-title: Mol. Cancer doi: 10.1186/s12943-019-0941-2 contributor: fullname: Yin – volume: 132 start-page: 2564 year: 2018 ident: 10.1016/j.xcrm.2023.101381_bib37 article-title: UCH-L1 bypasses mTOR to promote protein biosynthesis and is required for MYC-driven lymphomagenesis in mice publication-title: Blood doi: 10.1182/blood-2018-05-848515 contributor: fullname: Hussain – volume: 33 start-page: 3008 year: 2015 ident: 10.1016/j.xcrm.2023.101381_bib13 article-title: Advances in Risk Classification and Treatment Strategies for Neuroblastoma publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2014.59.4648 contributor: fullname: Pinto – volume: 9 start-page: 559 year: 2020 ident: 10.1016/j.xcrm.2023.101381_bib60 article-title: Hypermethylation of UCHL1 Promotes Metastasis of Nasopharyngeal Carcinoma by Suppressing Degradation of Cortactin (CTTN) publication-title: Cells doi: 10.3390/cells9030559 contributor: fullname: Zhao – volume: 30 start-page: 863 year: 2016 ident: 10.1016/j.xcrm.2023.101381_bib66 article-title: NUP98 Fusion Proteins Interact with the NSL and MLL1 Complexes to Drive Leukemogenesis publication-title: Cancer Cell doi: 10.1016/j.ccell.2016.10.019 contributor: fullname: Xu – volume: 44 start-page: 1104 year: 2012 ident: 10.1016/j.xcrm.2023.101381_bib29 article-title: Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer publication-title: Nat. Genet. doi: 10.1038/ng.2396 contributor: fullname: Peifer – volume: 30 start-page: 430 year: 2012 ident: 10.1016/j.xcrm.2023.101381_bib39 article-title: UCHL1 acts as a colorectal cancer oncogene via activation of the beta-catenin/TCF pathway through its deubiquitinating activity publication-title: Int. J. Mol. Med. doi: 10.3892/ijmm.2012.1012 contributor: fullname: Zhong – volume: 2472 start-page: 221 year: 2022 ident: 10.1016/j.xcrm.2023.101381_bib79 article-title: Metastasis Model to Test the Role of Notch Signaling in Prostate Cancer publication-title: Methods Mol. Biol. doi: 10.1007/978-1-0716-2201-8_18 contributor: fullname: Liu – volume: 34 start-page: 1652 year: 2016 ident: 10.1016/j.xcrm.2023.101381_bib52 article-title: Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2015.65.7270 contributor: fullname: Halabi – volume: 24 start-page: 1641 year: 2010 ident: 10.1016/j.xcrm.2023.101381_bib38 article-title: The de-ubiquitinase UCH-L1 is an oncogene that drives the development of lymphoma in vivo by deregulating PHLPP1 and Akt signaling publication-title: Leukemia doi: 10.1038/leu.2010.138 contributor: fullname: Hussain – volume: 7 start-page: 3 year: 2021 ident: 10.1016/j.xcrm.2023.101381_bib7 article-title: Small-cell lung cancer publication-title: Nat. Rev. Dis. Primers doi: 10.1038/s41572-020-00235-0 contributor: fullname: Rudin – volume: 11 start-page: 71 year: 2020 ident: 10.1016/j.xcrm.2023.101381_bib55 article-title: Integrative discovery of treatments for high-risk neuroblastoma publication-title: Nat. Commun. doi: 10.1038/s41467-019-13817-8 contributor: fullname: Almstedt – volume: 77 start-page: 654 year: 2017 ident: 10.1016/j.xcrm.2023.101381_bib72 article-title: LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics publication-title: Prostate doi: 10.1002/pros.23313 contributor: fullname: Nguyen – year: 2013 ident: 10.1016/j.xcrm.2023.101381_bib82 article-title: Patient-derived models of human breast cancer: protocols for in vitro and in vivo applications in tumor biology and translational medicine. publication-title: In Curr Protoc Pharmacol. doi: 10.1002/0471141755.ph1423s60 contributor: fullname: DeRose – volume: 11 start-page: 213 year: 2014 ident: 10.1016/j.xcrm.2023.101381_bib4 article-title: Small cell carcinoma of the prostate publication-title: Nat. Rev. Urol. doi: 10.1038/nrurol.2014.21 contributor: fullname: Nadal |
SSID | ssj0002511830 |
Score | 2.3423843 |
Snippet | Neuroendocrine carcinomas, such as neuroendocrine prostate cancer and small-cell lung cancer, commonly have a poor prognosis and limited therapeutic options.... |
SourceID | pubmedcentral proquest crossref pubmed elsevier |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 101381 |
SubjectTerms | Carcinoma, Neuroendocrine - drug therapy Carcinoma, Neuroendocrine - genetics Humans Lung Neoplasms - diagnosis Lung Neoplasms - drug therapy Male Membrane Glycoproteins neuroblastoma neuroendocrine carcinomas neuroendocrine prostate cancer nuclear pore complex small cell lung cancer Small Cell Lung Carcinoma Ubiquitin Thiolesterase - genetics Ubiquitin Thiolesterase - metabolism UCHL1 |
Title | UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas |
URI | https://dx.doi.org/10.1016/j.xcrm.2023.101381 https://www.ncbi.nlm.nih.gov/pubmed/38244540 https://search.proquest.com/docview/2917863857 https://pubmed.ncbi.nlm.nih.gov/PMC10897521 |
Volume | 5 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LSwMxEA5tD-JFFF_1USJ4k227m81uepRiKWLFg4VeJCTZLFZsWvoAf74zu02pDzx43U0gzExmvkm-mRByDTFGgxlEQRTnKkDAG-gk4Vicw5IsDrXiWDs8eEz6w_h-xEcVkvhamIK0b_S46d4nTTd-LbiVs4lpeZ5Y62nQDduik0LcaVVJFSx0K0dH_1uAZtZeV8iUZK4PM8ey84jhBwhSu2SHCYhsxaHH7wHpJ-D8zpvcCkS9fbK3RpD0tlzpAalYd0heht3-Q0jHC6robLpEChCMmfi3byneTBvMr6lyGd0quqIlFZwCdqVFb0vrsqnBkkBq8Jkhh_yhIzLs3T13-8H65YTAACBaBiKOYs1DprLY5onmSiiW88xCNhfBtrCsEyouRKLB1eURs1YpoZWNWZrqKBcpOyY1N3X2lNA26xjAbDEXFvY71wJBo9EG0hwO2RCvkxsvPjkrG2RIzxx7kyh3iXKXpdzrhHsJy3WIL0O3BA_-57wrrw4J9o-XGsrZ6WohI8g3BTgRntbJSamezTq8iutEfFHcZgD21v76B0yu6LHtTezs_1PP8QwA2WqwEdoXpLacr-wlIJilbhSZf6Mw208H_fF_ |
link.rule.ids | 230,315,730,783,787,867,888,27936,27937,53804,53806 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fT9swED7xQxq8TCBgdBvMk3hDoUlsJ-7jVA2VrUU8UIkXZNmOo3WibgVF2p-_u6RGhaE98JrYknN3vvsu_u4McIIxxqIZ5EkuapMQ4E1sUUgqzuFFJTJrJNUOjy6LwVj8uJE3a1DEWpiGtO_s5CzcTc_C5FfDrZxPXTfyxLpXo36Wql6Jcae7Dpu4YVOxkqWTB25gM0-XNTItneuPu6fC85zTAwxT2_COK4xtzW-P10PSv5DzJXNyJRSd78D7JYZk39q17sKaD3twO-4PhhmbPDDD5rMFkYBwzDTefsvobNpRhs1MqNhK2RVryeAM0Strulv6UM0cFQUyRxcNBWIQ7cP4_Pt1f5As705IHEKiRaJELqzMuKmErwsrjTK8lpXHfC7HjeF5LzNSqcKis6tz7r0xyhoveFnavFYlP4CNMAv-EFjKew5Rm5DK446XVhFsdNZhoiMxH5IdOI3i0_O2RYaO3LHfmuSuSe66lXsHZJSwXgb5Nnhr9OH_nfc1qkPjDqBjDRP87PFB55hxKnQjsuzAh1Y9T-uIKu6Aeqa4pwHUXfv5GzS6pst2NLKPb5_6BbYG16OhHl5c_vwE2_g1oqmGTz_DxuL-0R8hnlnY48Z4_wIzE_Pl |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dT9swED9tTEK8INBgK5-exNsUmsR24j6iblXZAPGwSrwgy3YcUUTdqi0Sfz53-UBlQ3vgNbEl5-5897v4d2eAE4wxFs0gjVJRmogAb2SzTFJxDs8KkVgjqXb48iobjsSvG3nTsCoXDa0yODs-DQ-T0zC-q7iVs4nrtjyx7vVlP4lVL8e4050VZfcjfMJNG2crmTp54Qo687ipk6kpXU9uTsXnKacHGKo2YJ0rjG_Vr4-3w9K_sPNv9uRKOBpswWaDI9lZvd5t-ODDZ7gd9YcXCRsvmGGz6ZKIQDhm0t6Ay-h82lGWzUwo2ErpFasJ4QwRLKs6XPpQTB0VBjJHlw0FYhHtwGjw809_GDX3J0QOYdEyUiIVVibcFMKXmZVGGV7KwmNOl-Lm8LyXGKlUZtHhlSn33hhljRc8z21aqpzvwlqYBv8VWMx7DpGbkMrjrpdWEXR01mGyIzEnkh343opPz-o2Gbrlj91rkrsmueta7h2QrYR1E-jrAK7Rj_933rdWHRp3AR1tmOCnjwudYtap0JXIvANfavW8rKNVcQfUK8W9DKAO26_foOFVnbZbQ9t7_9RjWL_-MdAX51e_92EDP0ZUBfHxAawt54_-ECHN0h5VtvsMtpL0-A |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=UCHL1+is+a+potential+molecular+indicator+and+therapeutic+target+for+neuroendocrine+carcinomas&rft.jtitle=Cell+reports.+Medicine&rft.au=Liu%2C+Shiqin&rft.au=Chai%2C+Timothy&rft.au=Garcia-Marques%2C+Fernando&rft.au=Yin%2C+Qingqing&rft.date=2024-02-20&rft.eissn=2666-3791&rft.volume=5&rft.issue=2&rft.spage=101381&rft_id=info:doi/10.1016%2Fj.xcrm.2023.101381&rft_id=info%3Apmid%2F38244540&rft.externalDocID=38244540 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2666-3791&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2666-3791&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2666-3791&client=summon |